Severe pulmonary hypertension: Critical care clinics

Critical Care Clinics

Volumn 17, Issue 2, 2001, Pages 453-467

  McLaughlin, Vallerie V ^b   Rich, Stuart ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CALCIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN;

ANTICOAGULANT THERAPY; HEART TRANSPLANTATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LUNG ARTERIOVENOUS SHUNT; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; REVIEW; SLEEP DISORDER; THROMBOEMBOLISM;

EID: 0034963691     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(05)70177-9     Document Type: Article

References (29)

1. Appetite-suppressant drugs and the risk of primary pulmonary hypertension
2. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease
3. A comparison of continuous intravenous epoprostenol prostacyclin with conventional therapy for primary pulmonary hypertension
4. Clinical types of chronic obstructive lung disease in London and in Chicago: A study of 100 patients
5. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension
6. Primary pulmonary hypertension: Natural history and the importance of thrombosis
7. The registry of the international society for heart and lung transplantation: Sixteenth official report - 1999
8. Long term domicillary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: A clinical trial
9. Lung transplantation: A decade of experience
10. Primary pulmonary hypertension and cirrhosis: Are they related?
11. Efficacy and safety of UT-15, a prostacyclin analog, for primary pulmonary hypertension
12. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
13. Should pulmonary hypertension be treated in chronic obstructive pulmonary disease?
14. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
15. Peripartum heart failure due to primary pulmonary hypertension
16. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease
17. HIV-associated primary pulmonary hypertension: A case control study
18. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): Hypothesis and design
19. Inhaled nitric oxide in primary pulmonary hypertension. A safe and effective agent for predicting response to nifedipine
20. Primary pulmonary hypertension: A national prospective study
21. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension
22. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
23. A short-term study of digoxin in patients with right ventricular dysfunction from pulmonary hypertension
24. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
25. Prostacyclin-induced pulmonary vasodilation in primary pulmonary hypertension
26. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment
27. Comparison of the effects of adenosine and nifedipine in pulmonary hypertension
28. Severe pulmonary hypertension associated with COPD
29. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease